SUTRO BIOPHARMA, INC. Cash And Cash Equivalents At Carrying Value

Quick Answer

SUTRO BIOPHARMA, INC. reported Cash And Cash Equivalents At Carrying Value of $58.13 million for the year ending 2025.

  • SUTRO BIOPHARMA, INC. showed a decrease of -69.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
  • XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 10 years of available data (2016 to 2025), SUTRO BIOPHARMA, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 401.4%.
  • Historical annual values: Fiscal year 2025: $58.13 million | Fiscal year 2024: $190.30 million | Fiscal year 2023: $69.27 million | Fiscal year 2022: $47.25 million | Fiscal year 2021: $30.41 million | Fiscal year 2020: $206.15 million | Fiscal year 2019: $4.96 million | Fiscal year 2018: $125.30 million | Fiscal year 2017: $22.02 million | Fiscal year 2016: $11.59 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: